Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients

David Vrabel, MSc, Jana Gregorova, MSc., Lenka Sedlarikova, MSc, Martina Almasi, Ing.,PhD, Renata Bezděková, MSc., Martin Stork, MD, Marta Krejci, Prof, MD PhD, Zdenek Adam, Prof, MD CSc, Ludek Pour, MD, Roman Hajek, MD PhD, Sabina Sevcikova, PhD

Blood (2018) 132 (Supplement 1): 3188.

https://doi.org/10.1182/blood-2018-99-114793

Published: 2018

Journal Articles

Diagnostic Relevance of 18F-FDG PET/CT in Newly Diagnosed Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) : Single- Center Experience

Viera Sandecka, MD PhD, Ludek Pour, MD, Zdenek Adam, Prof, MD CSc, Martin Stork, MD, Marta Krejci, Prof, MD PhD, Jana Michalcova, MD, Zdenek Kral, MD CSc, Sabina Sevcikova, PhD, Zdeněk Řehák, MD PhD, Renata Koukalova, MD

Blood (2018) 132 (Supplement 1): 1913.

https://doi.org/10.1182/blood-2018-99-111094

Published: 2018

Journal Articles

Risk Factors Associated with Development of Extramedullary Disease in Multiple Myeloma

Blood (2018) 132 (Supplement 1): 5596.

https://doi.org/10.1182/blood-2018-99-114854

Published: 2018

Journal Articles

Bortezomib-Based Induction Treatment for Patients with Multiple Myeloma Ineligible for Autologous Stem Cell Transplantation: A Retrospective Multicenter Study in Czech Republic

Viera Sandecka, MD, Ludek Pour, Doc,MD PhD, Sabina Sevcikova, RNDr, PhD, Lucie Brozova, MSc, Jan Straub, MD, Vlastimil Scudla, Prof, MD CSc, Vladimir Maisnar, Prof, MD PhD, Petr Pavlicek, MD, Zdenek Adam, Prof, MD CSc, Marta Krejci, Prof, MD PhD, Martin Stork, MD, Tomas Jelinek, Hana Plonkova, Roman Hajek

Blood (2017) 130 (Supplement 1): 5435.

https://doi.org/10.1182/blood.V130.Suppl_1.5435.5435

Published: 2017

Journal Articles

Identification of Phenotype Profile Related to the Extramedullary Involvement in Multiple Myeloma Relapse

Lucie Rihova, PhD, Pavla Vsianska, MSc, Renata Bezdekova, MSc, Zdenek Adam, prof, MD PhD, Miroslav Penka, prof, MD PhD, Tomas Jelinek, MD, Sabina Sevcikova, RNDr, PhD, Ludek Pour, MD PhD, Roman Hájek, prof, MD PhD

Blood (2016) 128 (22): 5653.

https://doi.org/10.1182/blood.V128.22.5653.5653

Published: 2016

Journal Articles

Deregulated Expression of Long Non-Coding RNAs UCA1, NEAT1 and BDNF-As in Multiple Myeloma

Lenka Sedlarikova, MSc, Barbora Gromesova, MSc, Jana Filipova, MSc, Veronika Kubaczkova, MSc, Lenka Radova, PhD, Martina Almasi, PhD, Miroslav Penka, MD PhD, Zdenek Adam, MD PhD, Ludek Pour, MD PhD, Marta Krejci, MD PhD, Sabina Sevcikova, RNDr, PhD, Roman Hajek, prof, MD PhD

Blood (2016) 128 (22): 2073.

https://doi.org/10.1182/blood.V128.22.2073.2073

Published: 2016

Journal Articles

Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population

Blood (2016) 128 (22): 3333.

https://doi.org/10.1182/blood.V128.22.3333.3333

Published: 2016

Journal Articles

Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients]

Blood (2014) 124 (21): 2071.

https://doi.org/10.1182/blood.V124.21.2071.2071

Published: 2014

Journal Articles

Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients

Lenka Kubiczkova-Besse, Lenka Sedlarikova, Fedor Kryukov, Lenka Radova, PhD, Jana Nekvindova, Pavel Nemec, Daniela Drandi, Simona Caltagirone, Paola Omedè, PhD, Marta Krejci, As Prof, MD PhD, Zdenek Adam, prof, MD PhD, Ludek Pour, Doc, MD PhD, Sabina Sevcikova, PhD, Antonio Palumbo, MD, Mario Boccadoro, Roman Hajek, Prof, MD PhD

Blood (2014) 124 (21): 2043.

https://doi.org/10.1182/blood.V124.21.2043.2043

Published: 2014

Journal Articles

Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG)

Jan Straub, MD, Roman Hajek, Vlastimil Scudla, prof, MD PhD, Vladimir Maisnar, As Prof, MD PhD, Evzen Gregora, Miroslava Schutzova, Zdenek Adam, prof, MD PhD, Jaroslav Bacovsky, MD PhD, Ivan Spicka, Prof. MD PhD

Blood (2014) 124 (21): 5682.

https://doi.org/10.1182/blood.V124.21.5682.5682

Published: 2014

Journal Articles

Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic

Blood (2014) 124 (21): 3376.

https://doi.org/10.1182/blood.V124.21.3376.3376

Published: 2014

Journal Articles

Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients

Lenka Kubiczkova-Besse, Daniela Drandi, Lenka Sedlarikova, Stefania Oliva, MD, Manuela Gambella, Paola Omedè, PhD, Zdenek Adam, prof, MD PhD, Ludek Pour, Doc, MD PhD, Sabina Sevcikova, PhD, Mario Boccadoro, MD, Antonio Palumbo, MD, Roman Hajek, Prof, MD PhD

Blood (2014) 124 (21): 3423.

https://doi.org/10.1182/blood.V124.21.3423.3423

Published: 2014

Journal Articles

Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group

Blood (2014) 124 (21): 2117.

https://doi.org/10.1182/blood.V124.21.2117.2117

Published: 2014

Journal Articles

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

Heinz Ludwig, Hedwig Kasparu, Clemens Leitgeb, Elisabeth Rauch, Werner Linkesch, Niklas Zojer, Richard Greil, Adelheid Seebacher, Ludek Pour, Adalbert Weißmann, Zdeněk Adam

Blood (2014) 123 (7): 985–991.

https://doi.org/10.1182/blood-2013-08-521468

Published: 2014

Journal Articles

Combination Of Lenalidomide, Dexamethasone and Cyclophosphamide as Treatment For The First Relapse Of Multiple Myeloma: Efficacy, Toxicity and Occurance Of Thyroid Abnormalities

Marta Krejci, MD, PhD, Zdenek Adam, Prof. MD, PhD, Ludek Pour, MD, PhD, Jana Pelcova, Jiri Mayer, MD, PhD

Blood (2013) 122 (21): 3233.

https://doi.org/10.1182/blood.V122.21.3233.3233

Published: 2013

Journal Articles

Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Prognostic Significance of Complete Response.

Marta Krejci, MD, PhD, Roman Hajek, Prof. MD, PhD, Zdenek Adam, Prof. MD, PhD, Ludek Pour, MD, PhD, Lenka Zahradova, MD, PhD, Jana Pelcova, Jiri Mayer, M.D., PhD., Prof.

Blood (2012) 120 (21): 3126.

https://doi.org/10.1182/blood.V120.21.3126.3126

Published: 2012

Journal Articles

High-Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma Group

Roman Hajek, Prof. MD, PhD, Ivan Spicka, As. Prof. MD, PhD, Vladimir Maisnar, As. Prof. MD, PhD, Tomas Pika, MD, PhD, Evzen Gregora, MD, Lenka Zahradova, MD, PhD, Jan Straub, MD, Jakub Radocha, MD, PhD, Jiri Minarik, MD, PhD, Petr Pavlicek, MD, Marta Krejci, As. Prof. MD, PhD, Ludek Pour, MD, PhD, Zdenek Adam, Prof. MD, PhD, Vlastimil Scudla, Prof. MD, PhD

Blood (2012) 120 (21): 4528.

https://doi.org/10.1182/blood.V120.21.4528.4528

Published: 2012

Journal Articles

Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated

Heinz Ludwig, Hedwig Kasparu, Richard Greil, MD, Clemens Leitgeb, Ercan Müldür, Elisabeth Rauch, Niklas Zojer, Eva Maria Autzinger, Werner Linkesch, Thomas Kuhr, Ludek Pour, MD, PhD, Zdenek Adam

Blood (2012) 120 (21): 943.

https://doi.org/10.1182/blood.V120.21.943.943

Published: 2012

Journal Articles

Significant Activity of Lenalidomide-Dexamethasone in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure (LC-ARF)

Heinz Ludwig, Elisabeth Rauch, Thomas Kuhr, Adalbert Weissman, Daniel Heintel, Niklas Zojer, Hedwig Kasparu, Richard Greil, MD, Zdenek Adam

Blood (2012) 120 (21): 4031.

https://doi.org/10.1182/blood.V120.21.4031.4031

Published: 2012

Journal Articles

Extramedullary Relapse of Multiple Myeloma - Plasma Cells Characteristics.

Ludek Pour, MD, PhD, Sabina Sevcikova, PhD, Lucie Rihova, PhD, Lenka Kubiczkova, M.Sc., Henrietta Greslikova, M.Sc., Renata Kupska, Fedor Kryukov, MD, Elena Dementyeva, MD, Aneta Mikulasova, M.Sc., Lenka Zahradova, MD, PhD, Zdenek Adam, Prof. MD, PhD, Roman Hajek, Prof. MD, PhD

Blood (2012) 120 (21): 2935.

https://doi.org/10.1182/blood.V120.21.2935.2935

Published: 2012

NARROW

Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients

Diagnostic Relevance of 18F-FDG PET/CT in Newly Diagnosed Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) : Single- Center Experience

Risk Factors Associated with Development of Extramedullary Disease in Multiple Myeloma

Bortezomib-Based Induction Treatment for Patients with Multiple Myeloma Ineligible for Autologous Stem Cell Transplantation: A Retrospective Multicenter Study in Czech Republic

Identification of Phenotype Profile Related to the Extramedullary Involvement in Multiple Myeloma Relapse

Deregulated Expression of Long Non-Coding RNAs UCA1, NEAT1 and BDNF-As in Multiple Myeloma

Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population

Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients]

Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients

Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG)

Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic

Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients

Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

Combination Of Lenalidomide, Dexamethasone and Cyclophosphamide as Treatment For The First Relapse Of Multiple Myeloma: Efficacy, Toxicity and Occurance Of Thyroid Abnormalities

Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Prognostic Significance of Complete Response.

High-Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma Group

Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated

Significant Activity of Lenalidomide-Dexamethasone in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure (LC-ARF)

Extramedullary Relapse of Multiple Myeloma - Plasma Cells Characteristics.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only